References
- Kim DH, Seo JW, Jung CS. The result of cause of death in 2003. Korea National Statistical office; 2004
- Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8 https://doi.org/10.1056/NEJMoa011954
- Hanna NH. Second-line chemotherapy for non-smallcell lung cancer: recent data with pemetrexed. Clin Lung Cancer 2004;5:S75-9 https://doi.org/10.3816/CLC.2004.s.007
- Bonomi PD. Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer. Clin Lung Cancer 2004;6:154-61 https://doi.org/10.3816/CLC.2004.n.028
- Ardizzoni A, Tiseo M. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). J Chemother 2004;16:104-7 https://doi.org/10.1179/joc.2004.16.Supplement-1.104
- Comis RL. The current situation: erlotinib and gefitinib in non-small cell lung cancer. Oncologist 2005; 10:467-70 https://doi.org/10.1634/theoncologist.10-7-467
- Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorebine: an overview. Cancer Treat Rev 1996;22: 127-42 https://doi.org/10.1016/S0305-7372(96)90032-8
- Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A phase II study of vinorelbine in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991;14:115-9 https://doi.org/10.1097/00000421-199104000-00004
- Furuse K, Kubota K, Kawahara M, Ogawara M, Kinuwaki E, Motomiya M, et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untrated advanced non-small cell lung cancer. Lung Cancer 1994;11:385-91 https://doi.org/10.1016/0169-5002(94)92167-9
- Carrato A, Rosell R, Camps C, Anton A, Garcia-Gomez R, Aranda E, et al. Modified weekly regimen with vinorelbine as a single agent in unresectable nonsmall cell lung cancer. Lung Cancer 1997;17:261-9 https://doi.org/10.1016/S0169-5002(97)00029-9
- Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, et al. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma. Cancer 2002;95:340-53 https://doi.org/10.1002/cncr.10629
- Sander AB, Nemunaitis J, Denham C, von Pauel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic nonsmall cell lung cancer. J Clin Oncol 2000;18:122-30 https://doi.org/10.1200/JCO.2000.18.1.122
- Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994;12:1535-40 https://doi.org/10.1200/JCO.1994.12.8.1535
- Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, de Marinis F, et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cance: a phase II study. J Clin Oncol 1997;15:297-303 https://doi.org/10.1200/JCO.1997.15.1.297
- Laack E, Mende T, Benk J, Cheaissani A, Scholtze J, Lorenz C, et al. Gemcitabine and vinorelbine as first-line therapy for non-small cell lung cancer: a phase II trial. Eur J Cancer 2001;37:583-90 https://doi.org/10.1016/S0959-8049(00)00441-X
- Shepherd FA. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. Anticancer Drugs 1995; 6:19-25
- Gridelli C, Perrone F, Gallo C, de Marinis F, Ianniello G, Cigolari S, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer: a two stage phage II study. Eur J Cancer 1997;33:392-7 https://doi.org/10.1016/S0959-8049(97)89011-9
- Hainsworth JD, Burris HA 3rd, Litchy S, Erland JB, Hon JK, Brierre JE, et al. Gemcitabine and vinorelbine in the second-line treatment of non-small cell lung carcinomas patients. Cancer 2000;88:1353-8 https://doi.org/10.1002/(SICI)1097-0142(20000315)88:6<1353::AID-CNCR11>3.0.CO;2-A
- Camps C, Martinez EN, Jaime AB. Second-line treatment with gemcitabine and vinorelbine in non-small cell lung cancer (NSCLC) cisplatin failures: a pilot study. Lung Cancer 2000;27:47-53 https://doi.org/10.1016/S0169-5002(99)00092-6
-
Kosmas C, Tsavaris N, Panopoulos C, Vadiaka M, Stavroyianni N, Kourelis T, et al. Gemcitabine and vinorelbine as second-line therapy in non-small cell lung cancer after prior treatment with
$taxene^{+}$ platinum-based regimens. Eur J Cancer 2001;37:972-8 https://doi.org/10.1016/S0959-8049(00)00419-6 - Pectasides D, Kalofonos HP, Samantas E, Nicolaides C, Papacostas P, Onyenadum A, et al. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: a phase II study of the Hellenic co-operative oncology group. Anticancer Res 2001;21:3005-10
- Jang PS, Kang HM, Lee JE, Kwon SJ, An JY, Lee YS, et al. Gemcitabine plus vinorelbine as second-line chemotherapy of the patients of previously treated non-small cell lung cancer. Tuberc Respir Dis 2005; 58:344-51 https://doi.org/10.4046/trd.2005.58.4.344
- Park YH, Lee JC, Kim CH, Ryoo BY, Kim HT. Gemcitabine and vinorelbine as second-line therapy for nonsmall cell lung cancer after treatment with paclitaxel plus platinum. Jpn J Clin Oncol 2004;34:245-9 https://doi.org/10.1093/jjco/hyh043
- Georgoulias V, Samonis G, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, et al. Comparision of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung cancer 2001;34:S47-51 https://doi.org/10.1016/S0169-5002(01)00417-2
- Georgoulias V, Scagliotti G, Miller V, Eckardt J, Douillard JY, Manegold C. Challenging the platinum combinations: docetaxel combined with gemcitabine or vinorelbine in non-small cell lung caner. Semin Oncol 2001;28:15-21 https://doi.org/10.1053/sonc.2001.22538
- Kosmidis P. Interim results of a Phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small cell lung cancer. Oncology 2000;14:41-8